e-learning
resources
ERJ
2015
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Outcomes of beta-blocker use in pulmonary arterial hypertension: a propensity-matched analysis
Bandyopadhyay Debabrata, Bajaj Navkaranbir S., Zein Joe, Minai Omar A., Dweik Raed A.
Source:
Eur Respir J 2015; 46: 750-760
Journal Issue:
September
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Bandyopadhyay Debabrata, Bajaj Navkaranbir S., Zein Joe, Minai Omar A., Dweik Raed A.. Outcomes of beta-blocker use in pulmonary arterial hypertension: a propensity-matched analysis. Eur Respir J 2015; 46: 750-760
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Should we screen for hereditary pulmonary hypertension?
Patient with ankylosing spondylitis and pulmonary hypertension
Related content which might interest you:
Adherence to guidelines of anticoagulant prescription in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: an observational study
Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension
Year: 2020
Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Year: 2015
Risk stratification and medical therapy of pulmonary arterial hypertension
Source: Eur Respir J, 53 (1) 1801889; 10.1183/13993003.01889-2018
Year: 2019
The effects of beta-blocker therapy on systolic and diastolic function in pulmonary arterial hypertension: A randomized controlled trial
Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH
Year: 2014
Long-term safety and clinical effects of riociguat in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: Interim analysis of a phase II extension study
Source: Annual Congress 2010 - Pulmonary hypertension updates
Year: 2010
REVEAL: a contemporary US pulmonary arterial hypertension registry
Source: Eur Respir Rev 2012; 21: 8-18
Year: 2012
Bisoprolol in idiopathic pulmonary arterial hypertension: an explorative study
Source: Eur Respir J 2016; 48: 787-796
Year: 2016
Clinical sildenafil use in Belgian patients with pulmonary arterial hypertension (PAH)
Source: Annual Congress 2010 - Pulmonary circulation II
Year: 2010
Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study
Source: Eur Respir J, 50 (1) 1700217; 10.1183/13993003.00217-2017
Year: 2017
Riociguat for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Real-life data from the EXPERT registry
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Year: 2015
Population pharmacokinetics of imatinib in patients with pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013
A critical analysis of survival in pulmonary arterial hypertension
Source: Eur Respir Rev 2012 21:218-222
Year: 2012
The effects of beta-blocker therapy on heart rate, symptoms and exercise in pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013
Assessment of simvastatin treatment on pulmonary arterial hypertension
Source: Annual Congress 2008 - Pulmonary hypertension II
Year: 2008
Hospitalization in patients with pulmonary arterial hypertension: causes and outcomes
Source: Annual Congress 2009 - Pulmonary circulation I
Year: 2009
Characteristics and outcome of patients with pre-capillary pulmonary hypertension who were drained for tamponade: A monocentric study
Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment
Year: 2013
General and standard therapy of pulmonary arterial hypertension
Source: International Congress 2017 – Russian Programme 2017
Year: 2017
Effect of riociguat on pulmonary arterial compliance (PAC) in patients with CTEPH in the CHEST-1 study
Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots
Year: 2015
Risk assessment and prognosis in patients with pulmonary arterial hypertension receiving intravenous treprostinil
Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension
Year: 2019
Patterns of therapy with sildenafil among patients with pulmonary arterial hypertension (PAH)
Source: Annual Congress 2010 - Pulmonary circulation I
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept